Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program

Trial Profile

Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POP
  • Sponsors Biogen
  • Most Recent Events

    • 12 Sep 2019 Results published in the Biogen Media Release.
    • 12 Sep 2019 According to an Biogen Media release, data from this study are being presented at the 35th Congress of the European Committee for Treatment and Research in MS (ECTRIMS) and 24th Annual Conference of Rehabilitation in MS.
    • 12 Oct 2018 Interim results (n=963; data cut off Sep 2017) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top